JP Morgan Chase
PRME icon

JP Morgan Chase’s Prime Medicine PRME Stock Holding History

JP Morgan Chase’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.42M Sell
783,058
-27,037
-3% -$89.8K ﹤0.01% 4116
2026
Q2 		$3.01M Sell
810,095
-34,059
-4% -$113K ﹤0.01% 3879
2026
Q1 		$2.66M Buy
844,154
+408,444
+94% +$1.55M ﹤0.01% 3890
2025
Q4 		$1.51M Buy
435,710
+392,321
+904% +$1.75M ﹤0.01% 4316
2025
Q3 		$240K Buy
43,389
+10,354
+31% +$42.1K ﹤0.01% 5423
2025
Q2 		$81.6K Sell
33,035
-2,628
-7% -$4.05K ﹤0.01% 5696
2025
Q1 		$71K Buy
35,663
+23
+0.1% +$59 ﹤0.01% 5737
2024
Q4 		$104K Sell
35,640
-1,742
-5% -$6.12K ﹤0.01% 5745
2024
Q3 		$145K Sell
37,382
-805
-2% -$3.73K ﹤0.01% 5545
2024
Q2 		$196K Sell
38,187
-3,894
-9% -$23.6K ﹤0.01% 5173
2024
Q1 		$295K Sell
42,081
-3,438
-8% -$26.1K ﹤0.01% 5108
2023
Q4 		$403K Buy
45,519
+18,505
+69% +$143K ﹤0.01% 4930
2023
Q3 		$258K Sell
27,014
-3,658
-12% -$47.5K ﹤0.01% 4905
2023
Q2 		$449K Buy
30,672
+17,775
+138% +$248K ﹤0.01% 4554
2023
Q1 		$159K Buy
12,897
+3,023
+31% +$49.2K ﹤0.01% 5194
2022
Q4 		$184K Buy
+9,874
New +$178K ﹤0.01% 5079

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Alessandra Capital Management
Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return
Greenwich Wealth Management
Greenwich Wealth Management Greenwich, Connecticut $3.09B AUM 22.23% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $234M AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

JP Morgan Chase's PRME Position: Q3 2026 in Review

JP Morgan Chase reduced its Prime Medicine (PRME) stake by 3.3% in Q3 2026, selling an estimated $89.8K and leaving 783,058 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #4116.

JP Morgan Chase first reported a position in PRME in Q4 2022 and has held it in 16 quarters since. The position peaked at $3.01M in Q2 2026. 89 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • JP Morgan Chase held 783,058 shares of Prime Medicine worth $2.42M as of Q3 2026.
  • JP Morgan Chase sold 27,037 Prime Medicine shares in Q3 2026, an estimated $89.8K.
  • Prime Medicine made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #4116 holding.
  • JP Morgan Chase first reported a position in Prime Medicine in Q4 2022 and has held it in 16 quarters since.
  • JP Morgan Chase's Prime Medicine position peaked at $3.01M in Q2 2026.
  • 89 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.